Findings

What do systematic reviews say?

12 questions · 12 findings · 4 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 16.7%GRADE not reported 1 · 8.3%Very low 5 · 41.7%Low 2 · 16.7%Moderate 2 · 16.7%High 0 · 0%

Hypertonic saline 7% vs hypertonic saline

Adverse events · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 3% to 7% vs Normal saline

Adverse events · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 142 participants
Very low

Hypertonic saline 3% to 7% vs Normal saline

Adverse events · adults and children with cystic fibrosis (stable lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 513 participants
Low

Hypertonic saline vs Normal saline

Adverse events · people with bronchiectasis

Hypertonic saline showed no clear difference in adverse events compared with isotonic saline; GRADE not reported.

1 finding from 1 review

Inhaled hyperosmolar agents for bronchiectasis 2014 · Cochrane Headline outcomes only
OR 8.2 [0.4, 169.9]
1 study · 40 participants
GRADE not reported

Hypertonic saline vs rhDNase with

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Very low

Hypertonic saline vs amiloride

Adverse events · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Very low

Hypertonic saline vs mannitol

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Very low

Nebulised hypertonic saline vs nebulised 0.9% saline

Adverse events Assessed by investigators or reported by parents · infants up to 24 months of age with acute bronchiolitis

1 finding from 1 review

Nebulised hypertonic saline solution for acute bronchiolitis in infants 2023 · Cochrane Headline outcomes only
no estimate extracted
27 studies · 4416 participants
Low

Hypertonic saline 7% vs xylitol

Adverse events: serious adverse events · adults with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 89 participants
Very low

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy (hypertonic saline) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.89 [0.58, 1.36]
2 studies · 288 participants
Moderate

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (hypertonic saline) probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.74 [0.59, 0.93]
2 studies · 288 participants
Moderate